Extended duration use of menopausal hormone therapy

Menopause

Volumn 21, Issue 6, 2014, Pages 679-681

  Kaunitz, Andrew M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN;

ARTICLE; DYSPAREUNIA; FEMALE; HORMONAL THERAPY; HUMAN; OSTEOPOROSIS; OVERACTIVE BLADDER; TREATMENT DURATION; URINARY TRACT INFECTION; UTERUS; VAGINAL DRYNESS; VASOMOTOR DISORDER; HORMONE SUBSTITUTION; HOT FLASHES; INTRAVAGINAL DRUG ADMINISTRATION; MENOPAUSE; TIME;

ADMINISTRATION, INTRAVAGINAL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MENOPAUSE; OSTEOPOROSIS; TIME FACTORS;

EID: 84901639260     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000175     Document Type: Article

References (23)

1. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
2. Nelson HD. Postmenopausal estrogen for treatment of hot flashes: clinical applications. JAMA 2004;291:1621-1625.
3. Hulley SB, Grady D. The WHI estrogen-alone trial-do things look any better? JAMA 2004;291:1769-1771.
4. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095-1104.
5. Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008;168:840-846.
6. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451.
7. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779-787.
8. Menostar Prescribing Information. Wayne, NJ: Bayer, 2007.
9. Diem S, Grady D, Quan J, et al. Effects of ultralow-dose transdermal estradiol on postmenopausal symPART.oms in women aged 60 to 80 years. Menopause 2006;13:130-138.
10. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110: 771-779.
11. Premarin Prescribing Information. Philadelphia, PA: Pfizer, 2012.
12. National Osteoporosis Foundation. Clinician-s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2013.
13. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
14. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
15. Sweetland S, Beral V, Balkwill A, et ala The Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10:2277-2286.
16. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contracePART.ion or postmenopausal hormone therapy. J Thromb Haemost 2013;11:124-131.
17. Renoux C, Dell-Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
18. Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052-1059.
19. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
20. Renoux C, Dell-Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
21. Lee JS, Yaffe K, Lui LY, et ala Study of Osteoporotic Fractures Group. Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol 2010;67:195-201.
22. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011;18:962-966.
23. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999; 80:1072-1079.